stocktitan.netAUG 143 min read$ARWR

Avoro Capital discloses 9.64% Arrowhead Pharmaceuticals (ARWR) stake including warrants

Arrowhead Pharmaceuticals (ARWR) disclosed that Avoro Capital Advisors LLC and controlling person Behzad Aghazadeh beneficially own 13,823,383 shares, including 2,467,828 shares issuable on warrant exercise. Using 140,857,021 shares outstanding as of May 1, 2026, the stake equals 9.64% assuming warrants are exercised.

Original reporting

stocktitan.net

Published Aug 14, 2026, 1:01 PM UTC

Analysis

alphai AI DeskAI-generated

Added to alphai Aug 14, 2026, 6:20 PM UTC. Informational, not investment advice.

How this was made

alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.

About alphai AI Desk Scoring methodology Report an issue

alphai market briefFinancial news

Primary signal

$ARWR

Neutral

medium confidence

Mentioned

$ARWR

Relevance

4/10

alphai data visualization · based on stocktitan.net

Decision brief

The 30-second read

$ARWRNeutralLow

Why it matters

The disclosure updates the shareholder register and may influence expectations around future governance or strategic positioning, but it does not provide new company fundamentals.

Market read

A near-10% beneficial ownership disclosure with warrant exposure can affect positioning and sentiment, but lacks operational or financial triggers.

What to watch

Traders should monitor whether warrants are exercised, whether the stake changes materially, and whether any separate 13D activist-style intent is later disclosed.

Relevance 4/10Novelty 5/10Timing: today’s disclosure of a Schedule 13G/A stake

Background

The filing is a Schedule 13G/A under the Securities Exchange Act, reporting beneficial ownership for investment purposes.

Company-level read

Ticker impact

AI estimates · verify against primary disclosures

$ARWRNeutralMedium confidence

Context

Avoro Capital Advisors disclosed a 9.64% beneficial stake in Arrowhead, including 2.47M shares issuable on warrant exercise.

Expected impact

Likely limited near-term impact; watch for follow-on filings or changes in stake size.

Evidence & confidence

The article is a regulatory ownership update (Schedule 13G) with no new clinical, financial, or deal terms. However, a near-10% holder can affect sentiment and future governance expectations.

Market effects

Sector

Minor read-through for biotech ownership concentration and potential activist or strategic interest, without sector-wide fundamentals.

Regional

No clear regional spillover beyond US small/mid-cap biotech sentiment.

Global

Primarily US-focused ownership transparency; no direct global catalyst described.

Counterpoint

What could challenge this read

A Schedule 13G/A can reflect passive investment intent, so the market may overreact to the headline ownership percentage.

Key entities

issuer
Arrowhead Pharmaceuticals, Inc.
US biotech company whose beneficial ownership stake was disclosed, including warrant-issuable shares.
reporting person
Avoro Capital Advisors LLC
Investment adviser reporting beneficial ownership of Arrowhead shares and warrants.
controlling person
Behzad Aghazadeh
Controlling person of Avoro reporting sole voting and dispositive power over the disclosed stake.

Read at source ← All news

SEP 4

$ARWRHighAI 9/10

Arrowhead (ARWR) Reported a 78% Lower Pancreatitis Event Rate With Plozasiran. Does the Absolute Benefit Support a Broader Label?

Arrowhead Pharmaceuticals (ARWR) reported Phase 3 trial results for plozasiran, showing 79-81% triglyceride reductions vs. 27% for placebo. Pooled analysis indicated a 78% reduction in pancreatitis events, but absolute risk reduction was 4.1%. ARWR plans to submit a broader-label application by 2026. Plozasiran is FDA-approved for familial chylomicronemia syndrome. The company aims to expand its use to severe hypertriglyceridemia. Triglyceride reductions were consistent, with 91-93% of treated p

insidermonkey.com2 min

AUG 31

$ARWRMedAI 8/10

Plozasiran durably cuts triglycerides, pancreatitis risk in severe hypertriglyceridemia

Plozasiran, an FDA-approved drug by Arrowhead, reduced triglycerides by up to 81% in severe hypertriglyceridemia patients and prevented pancreatitis. Two trials, SHASTA-3 and SHASTA-4, showed sustained reductions and favorable safety profiles. Gerald F. Watts, a cardiometabolic medicine professor, highlighted the therapy's potential impact on clinical practice. The drug is not yet approved for severe hypertriglyceridemia.

healio.com2 min

AUG 31

$ARWRHighAI 8/10

Arrowhead’s new Redemplo findings in severe hypertriglyceridemia have analysts split

Arrowhead Pharmaceuticals presented late-stage trial results for plozasiran (Redemplo) in severe hypertriglyceridemia, showing favorable safety and efficacy. Analysts are divided: Stifel highlights its safety and dosing advantages over Ionis' Tryngolza, while BMO favors Tryngolza due to glycemic control concerns. Arrowhead plans an FDA submission for expanded use later this year.

biospace.com3 min

AUG 30

$ARWRHighAI 8/10

Arrowhead Pharmaceuticals, Inc.: Arrowhead Pharmaceuticals Presents Phase 3 SHASTA-3 and SHASTA-4 Data Demonstrating Plozasiran Reduced Acute Pancreatitis Events in Patients with Severe Hypertriglycer

Arrowhead Pharmaceuticals presented Phase 3 data showing plozasiran reduced triglycerides by 79-81% and acute pancreatitis events by 78% in severe hypertriglyceridemia patients. Over 90% of patients achieved TG levels below 500 mg/dL. The company plans to file an FDA application by year-end 2026, utilizing a Priority Review Voucher. Plozasiran demonstrated a favorable safety profile.

finanznachrichten.de2 min

AUG 17

$ARWRMedAI 8/10

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Arrowhead Pharmaceuticals (NASDAQ: ARWR) said the European Commission approved REDEMPLO (plozasiran) in June 2026, and it is now listed in Germany’s Lauer-Taxe database for prescribing and reimbursement. REDEMPLO is used with diet for adult FCS patients, with dosing as a subcutaneous injection every three months. Phase 3 PALISADE showed significant fasting triglyceride reductions at Month 10 versus placebo; common adverse reactions included hyperglycaemia and headache.

ir.arrowheadpharma.com4 min

AUG 11

$ARWRMed

How Investors Are Reacting To Arrowhead Pharmaceuticals (ARWR) Soaring Sales But Deepening Losses

Arrowhead Pharmaceuticals (ARWR) reported Q3 2026 results. Sales rose to $75.25 million from $27.77 million a year earlier, but net loss widened to $194.28 million and loss per share increased to $1.36 from $1.26. For the first nine months of 2026, it swung to a $296.21 million net loss despite $400+ million in sales, citing higher expenses and lower collaboration revenue.

simplywall.st6 min